The average EPS estimate for Argos Therapeutics, Inc. (NASDAQ:ARGS) for the three months ending 2016-12-31 is given as $-0.29.
You find that 7 days ago, the average EPS estimate on the stock was $-0.29, while for the 30 days ago the average EPS estimate stood at $-0.29.
If you look back further, you see that the average EPS estimate for Argos Therapeutics, Inc. (NASDAQ:ARGS) 60 days ago was given as -0.29, while EPS estimate 90 days ago was quoted at $-0.29.
The change in the stock’s EPS estimate over the last 7 days works out to 0.16%.
EPS estimate revisions
Over the last 7 days, EPS estimates for Argos Therapeutics, Inc. (NASDAQ:ARGS) have been revised up 2 times. In the same period, the EPS estimate has been revised down 1 times.
In the last 30 days, the stock has had its EPS estimate revised up 3 and it has been revised up 3 times over the last 60 days.
Up revisions in the last 90 days are 3 and up revisions in the last 120 days are 3.
But for the last 18 days, the company has seen its EPS revised up 2 times, offset by 0 down revisions in the same period.
The down revisions of EPS in last 30, 60, 90 and 120 days were 1, 1, 1 and 0.
What About EPS Surprises
Analysts predicted EPS of $-0.29 for Argos Therapeutics, Inc. (NASDAQ:ARGS) for the period ended 2. But the company ended up posting actual EPS of $-0.48 on 2016-08-10. The EPS estimate cited was worked out based on 4 estimates that analysts had issued on the stock.
Therefore, Argos Therapeutics, Inc. (NASDAQ:ARGS) posted EPS surprise of $-0.08 per share in dollar terms, which works out to -20%. The standard deviation of the actual EPS reported by the company and the average EPS estimate immediately before the earnings were released works out to $0.06.
Quarterly Sales Estimates
For the fiscal year 2016, the mean and median annual sales estimates for the company are given as $0.316 and $0.26. The estimates are based on the projections of 3 analysts.
So far, the highest annual sales estimate for Argos Therapeutics, Inc. (NASDAQ:ARGS) stands at$0.49. That compares with the lowest annual sales estimate of $0.2. Calculating the standard deviation of the extreme annual sales estimates leads you to 0.153%.
Annual sales estimate adjustments
In the last 7 days, 3 analysts have raised their annual sales estimates for the company. But over the same period, 3 analysts have trimmed their annual sales estimates.
With that, you find that the percentage change in mean annual sales estimate in the last 7 days works out to -78.791%.
Over the last one month, though, 3 analysts moved to raise their sales estimates for Argos Therapeutics, Inc. (NASDAQ:ARGS). That compares with 3 analysts who cut their sales estimate for the company in the same period. That leads you to -78.791% as the mean sales estimate change over the last one month.
If you look back further, you see that over the last three months, 3 analysts have moved raise their sales estimates Argos Therapeutics, Inc. (NASDAQ:ARGS). That offset by 3 analysts who in the same period lowered their sales estimates for the stock. That works out to percentage change in mean sales estimate of 209.803% over a period of three months.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...